SCHEMBL355161

SCHEMBL355161

CC(C)(C)OC(=O)N1CCN(c2ccc(C(=O)O)cc2Br)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
KMT2A Q03164 4/20 0.47
MEN1 O00255 3/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
BACE1 P56817 2/20 0.46
ESRRB O95718 1/20 0.46
ESR1 P03372 1/20 0.46
ESRRA P11474 1/20 0.46
ESRRG P62508 1/20 0.46
GBA1 P04062 2/20 0.45
GPR119 Q8TDV5 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP2C19 P33261 1/20 0.44
SMARCA2 P51531 1/20 0.44
SMARCA4 P51532 1/20 0.44
PBRM1 Q86U86 1/20 0.44
CKS1B P61024 1/20 0.44
SKP1 P63208 1/20 0.44
SKP2 Q13309 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256162 0.88 LMNA (0.54) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL20516367 0.86 MEN1 (0.54) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL532058 0.86 POLB (0.49) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL354715 0.85 L3MBTL1 (0.59) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL30858329 0.85 L3MBTL1 (0.59) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL17756947 0.84 L3MBTL1 (0.51) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL4929222 0.84 LMNA (0.49) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL5914044 0.83 MAPT (0.48) LMNAALDH1A1MAPTBACE1SMN1; SMN2
SCHEMBL27141490 0.83 MEN1 (0.54) LMNAKMT2AMEN1ALDH1A1MAPT
SCHEMBL1478500 0.82 TTR (0.52) LMNAKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-01-19 US disclosed
WO-2009079593-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015957-A1 PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR NPY2R, NPY1R, NPY5R LMNA 3781/4885KMT2A 3251/4885MEN1 2605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.